GSK Pharma shares jump 20% as net profit jumps five-fold to ₹229 crore

After opening at ₹2,239.95, shares of the drug major were trading at ₹2,405 apiece during the intraday trade on BSE, surging 19.19%. At 1:30 PM, the stock was trading 17.95% higher.

However, the pharma stock remains below its 52-week high of ₹3,087.95, recorded in August 2024. It had hit a 52-week low in April 2024, which was at ₹1,825.05.

GlaxoSmithKline Pharmaceuticals on Friday reported its net profit at ₹229 crore for the third quarter ended December 31, 2024, increasing fivefold. The drug firm reported a net profit of ₹45 crore for the October-December quarter of last fiscal.

Revenue from operations rose to ₹949 crore for the third quarter, as compared to ₹805 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement.

"Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India," GlaxoSmithKline Pharmaceuticals managing director Bhushan Akshikar had said.

By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, the company continues to strengthen its market presence while ensuring broader access to medicines and vaccines, he added.

The company saw strong performance across key product portfolios during the quarter, the drug firm said.

Flagship brands within the general medicines’ portfolio, including Augmentin, Ceftum, and T-bact, strengthened their market positions with share gains, it added.

In the vaccines segment, GSK maintained its leadership in the self-pay private market for paediatric vaccines, it said.

GlaxoSmithKline Pharmaceuticals is a subsidiary of GSK plc, a global healthcare company dedicated to leveraging science, technology, and talent to address disease challenges worldwide.